Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
The invention provides certain amino-pyrimidine-containing compounds. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
1. A compound of the Formula (I)
or a pharmaceutically acceptable salt thereof, wherein
R 1 is C 1 -C 3 alkyl; and
R 6 is C 1 -C 3 fluoroalkyl.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 is —CF 3 .
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is —CH 3 .
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is
5. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
6. A method of treating asthma or chronic obstructive pulmonary disease comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof.
7. A method of treating asthma or chronic obstructive pulmonary disease comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent to a patient in need thereof.
8. A pharmaceutical composition comprising the compound of claim 4 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
9. A method of treating asthma or chronic obstructive pulmonary disease comprising administering a therapeutically effective amount of the compound of claim 4 or a pharmaceutically acceptable salt thereof to a patient in need thereof.
10. A dry powder inhalable composition comprising a dry powder blend of lactose and the compound of claim 1 or a pharmaceutically acceptable salt thereof.